Aldehyde Dehydrogenase Activity Distinguishes Leukemia Stem Cells from Normal Hematopoietic Stem Cells in Acute Myeloid Leukemia

Case ID:
C11237
Disclosure Date:
9/20/2010
Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34+CD38? cells capable of engrafting immunodeficient mice, from residual normal hematopoietic stem cells that exhibited relatively higher ALDH activity. Minimal residual disease (MRD) detected during complete remission was enriched for the CD34+CD38?ALDHint leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse. The methods of the present invention can distinguish normal from leukemic CD34+CD38? cells, and identifies those AML cells associated with relapse. Methods of prediction of relapse of AML patients and methods of treatment are also provided.
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Aldehyde Dehydrogenase Activity Distinguishes Leukemia Stem Cells from Normal Hematopoietic Stem Cells in Acute Myeloid Leukemia ORD: Ordinary Utility United States 13/625,369 9,012,215 9/24/2012 4/21/2015 9/24/2032 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Nakisha Holder
nickki@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum